PBAC Public Summary Documents - November 2019
Page last updated: 20 March 2020
Public Summary Documents relating to the November 2019 PBAC meeting.
- Adalimumab: Injection 80 mg in 0.8 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe; Humira®
- Alectinib: Capsule 150 mg; Alecensa®; Crizotinib: Capsule 200 mg; Capsule 250 mg; Xalkori®
- Amino acid formula with carbohydrate without phenylalanine: Tablet 1.25 g, 462; PKU Easy Tablet®
- Amino acid formula with fat, carbohydrate without methionine: Tablets 0.91g, 462; HCU Easy®
- Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine: Tablets 0.91g, 462; TYR Easy®
- Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine: Tablets 1.25 g, 462; MSUD Easy Tablet®
- Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Sachet containing oral powder 12.5 g, 30; MSUD explore5®
- Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL; Tecentriq®
- Atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq®
- Authorised Nurse Practitioner prescribing for Hepatitis B, Hepatitis C and Human Immunodeficiency Virus medicines under the Highly Specialised Drugs (HSD) Program
- Belimumab: Injection 200 mg in 1 mL pre-filled pen; Benlysta®
- Botulinum toxin type A purified neurotoxin complex: Lyophilised powder for injection 100 units; Botox®
- Brigatinib : Tablet 30 mg, Tablet 90 mg, Tablet 180 mg, Pack containing 7 tablets containing brigatinib 90 mg and 21 tablets containing brigatinib 180 mg; Alunbrig®
- Brivaracetam: Tablet 25 mg, Tablet 50 mg, Tablet 75 mg, Tablet 100 mg, Oral solution 10mg per mL, 300 mL; Briviact®
- Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu®
- Budesonide with Formoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses, Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses; Symbicort Turbuhaler® 200/6; Symbicort Rapihaler® 100/3
- Buprenorphine: Injection (modified release) 100 mg in 0.5 mL pre-filled syringe, Injection (modified release) 300 mg in 1.5 mL pre-filled syringe; Sublocade®
- Buprenorphine with Naloxone: Tablet (sublingual) containing 0.7 mg buprenorphine hydrochloride with 0.18 mg naloxone hydrochloride, Tablet (sublingual) containing 1.4 mg buprenorphine hydrochloride and 0.36 mg naloxone hydrochloride, Tablet (sublingual) containing 2.9 mg buprenorphine hydrochloride and 0.71mg naloxone hydrochloride, Tablet (sublingual) containing 5.7 mg buprenorphine hydrochloride and 1.4 mg naloxone hydrochloride, Tablet (sublingual) containing 8.6 mg and 2.1mg naloxone hydrochloride, Tablet (sublingual) containing 11.4 mg buprenorphine hydrochloride and 2.9 mg naloxone hydrochloride; Zubsolv®
- Certolizumab pegol: Injection 200 mg in 1 mL single use pre-filled syringe, Solution for injection 200 mg in 1 mL pre-filled pen; Cimzia®
- Certolizumab pegol: Solution for injection 200mg in 1 mL pre-filled pen, Solution for injection 200 mg in 1 mL single use pre-filled syringe; Cimzia®
- Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex®
- Darunavir with Cobicistat with Emtricitabine and Tenofovir alafenamide: Tablet containing darunavir 800 mg with cobicistat 150 mg with emtricitabine 200 mg and tenofovir alafenamide 10 mg; Symtuza®
- Dimethyl fumarate: Capsule (modified release) 120 mg, Capsule (modified release) 240 mg; Tecfidera®
- Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen; Trulicity®
- Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®
- Evolocumab: Injection 420 mg in 3.5 mL single use pre-filled cartridge Injection 140 mg in 1 mL single use pre-filled pen; Repatha®
- Fremanezumab: Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy®
- Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 16 g, 60, Sachets containing oral powder 32 g, 30; PKU Build 10®; PKU Build 20®
- High dose inactivated trivalent Influenza vaccine (split virion): Injection 0.5 mL; Fluzone® High-Dose
- Ibrutinib: Capsule 140 mg; Imbruvica®
- Inactivated quadrivalent Influenza vaccine (split virion): Injection 0.5 mL; FluQuadri TM
- Incobotulinumtoxin A: Lyophilised powder for injection 100 units; Xeomin®
- Isotretinoin: Capsule 30 mg; Oratane®
- Levodopa with Carbidopa: Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL; Duodopa®
- Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua®
- Multicomponent Meningococcal group B vaccine: Injection 0.5 mL; Bexsero®
- Neratinib: Tablet 40 mg; Nerlynx®
- Nivolumab and Ipilimumab: nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL, Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® Yervoy®
- Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Olaparib: Tablet 100 mg, Tablet 150 mg ; Lynparza®
- Patiromer: Powder for oral liquid 8.4 g, Powder for oral liquid 16.8 g; Veltassa®
- Pegfilgrastim: Injection 6 mg in 0.6 mL single use pre-filled syringe; Ziextenzo®
- Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Polatuzumab vedotin: Powder for I.V. infusion 140 mg; Polivy®
- Pomalidomide: Capsule 3 mg, Capsule 4 mg; Pomalyst®
- Prednisolone with Phenylephrine: Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL; Prednefrin® Forte
- Primidone: Tablet 250 mg; APO‑Primidone®
- Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A: Oral liquid 125 mL, 24; Renastep®
- Ruxolitinib: Tablet 5 mg, Tablet 10 mg, Tablet 15 mg, Tablet 20 mg; Jakavi®
- Salbutamol: Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation); Ventolin®
- Semaglutide: Injection 2 mg in 1.5 mL pre-filled syringe, Injection 4 mg in 3 mL pre-filled syringe; Ozempic®Semaglutide: Injection 2 mg in 1.5 mL pre-filled syringe, Injection 4 mg in 3 mL pre-filled syringe; Ozempic®
- Siponimod: Tablet 250 micrograms, Tablet 2 mg; Mayzent®
- Tacrolimus: Capsule 3 mg (once daily prolonged release); Advagraf XL®
- Talazoparib: Capsule 250 micrograms (as tosilate), Capsule 1 mg (as tosilate); Talzenna®
- Tezacaftor with Ivacaftor: Tablet containing tezacaftor 100 mg with ivacaftor 150 mg; Symdeko®
- Tolvaptan: Tablets 15 mg, Tablets 30 mg, Pack containing 28 tablets 15 mg and 28 tablets 45 mg, Pack containing 28 tablets 30 mg and 28 tablets 60 mg, Pack containing 28 tablets 30 mg and 28 tablets 90 mg; Jinarc®
- Trastuzumab: Powder for I.V. infusion 60 mg, Powder for I.V. infusion 150 mg; Trazimera®
- Trastuzumab emtansine: Powder for I.V. infusion 100 mg, Powder for I.V. infusion 160 mg; Kadcyla®
- Trifluridine with Tipiracil: Tablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride), Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride); Lonsurf®
- Upadacitinib: Tablet (modified release) 15 mg; Rinvoq®
The following Public Summary Documents have been updated.
March 2019 PBAC meeting
July 2019 PBAC meeting
